Ratings Johnson & Johnson Swiss Exchange

Equities

JNJ

US4781601046

Market Closed - Swiss Exchange Other stock markets 16:36:28 25/05/2023 BST			5-day change	1st Jan Change
136 ^USD	-0.73%		-0.73%	-.--%

08:03pm	Some of the biggest splits in Corporate America	RE
05-22	Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies	RE

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's enterprise value to sales, at 4.1 times its current sales, is high.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JOHNSON & JOHNSON	-.--%	369B	-
ELI LILLY AND COMPANY	+38.69%	723B	C+
NOVO NORDISK A/S	+34.28%	595B	B
MERCK & CO., INC.	+20.24%	332B	B-
ABBVIE INC.	+2.12%	282B	C+
ASTRAZENECA PLC	+17.02%	244B	B+
NOVARTIS AG	+9.31%	208B	B-
ROCHE HOLDING AG	-5.07%	205B	A+
PFIZER, INC.	-0.35%	168B	C+
AMGEN INC.	+6.42%	166B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes